AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39507857 — intervention group
Group type: COMPARATOR
Intervention: Simulated LiSWT (Sham Control) converted to Active LiSWT
Number of subjects: 0
Study 39507860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiSWT), treated twice weekly for 3 consecutive weeks with a Storz device.
Number of subjects: 30
Study 39507860 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group), patients crossed over at 1 month and were unblinded.
Number of subjects: 30
Study 39507936 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation and home-based rehabilitation
Number of subjects: 168
Study 39507936 — intervention group
Group type: COMPARATOR
Intervention: No physical rehabilitation
Number of subjects: 168
Study 39508125 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell phenotypes obtained prior to transplantation
Number of subjects: 98
Study 39508125 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation in CD56 NK cell phenotypes
Number of subjects: 98
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher American Heart Association cardiovascular health score at baseline
Number of subjects: 504
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index-SD score
Number of subjects: 504
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure
Number of subjects: 504
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher moderate-to-vigorous physical activity
Number of subjects: 504
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Better cardiorespiratory fitness
Number of subjects: 504
Study 39508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lean mass
Number of subjects: 504
Study 39508144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intracoronary adenosine
Number of subjects: 102
Study 39508144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intracoronary adenosine (HDIC)
Number of subjects: 102
Study 39508144 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine
Number of subjects: 102
Study 39508283 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for UTIs in adults with intellectual disability and UI
Number of subjects: 20
Study 39508283 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment for UTI
Number of subjects: 20
Study 39508366 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Venu 2S
Number of subjects: 32
Study 39508366 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Vantage M2
Number of subjects: 32
Study 39508366 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Verity Sense
Number of subjects: 32
Study 39508366 — intervention group
Group type: EXPERIMENTAL
Intervention: Scosche Rhythm24
Number of subjects: 32
Study 39508366 — intervention group
Group type: COMPARATOR
Intervention: Medical-grade ECG
Number of subjects: 32
Study 39508562 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 300 mg subcutaneously every four weeks for 96 weeks
Number of subjects: 118
Study 39508562 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab treatment
Number of subjects: 118
Study 39508783 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ride-on cars (MROCs) training in standing postures
Number of subjects: 39
Study 39508783 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ride-on cars (MROCs) training in different postures
Number of subjects: 39
Study 39508888 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous carbon-dioxide monitoring (TCM)
Number of subjects: 726
Study 39508888 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 726
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic bariatric surgery (MBS)
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hs-CRP
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP change in first 6 months postoperatively
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir hs-CRP
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: % Total Weight Loss (%TWL) at 10 years
Number of subjects: 240
Study 39509008 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hs-CRP at baseline
Number of subjects: 240
Study 39509108 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) under the 48th percentile
Number of subjects: 1010
Study 39509108 — intervention group
Group type: COMPARATOR
Intervention: High polygenic risk group
Number of subjects: 1010
Study 39509108 — intervention group
Group type: COMPARATOR
Intervention: Early treatment (randomization to early treatment)
Number of subjects: 1010
Study 39509148 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic immediate VKA reversal with 25 IU/kg of four-factor prothrombin complex concentrate (4f-PCC) before any investigation.
Number of subjects: 202
Study 39509148 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care reversal only if the initial cranial CT scan indicated ICH.
Number of subjects: 202
Study 39509183 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39509229 — intervention group
Group type: EXPERIMENTAL
Intervention: Men reporting PMIEs on the MIQ-M
Number of subjects: 0
Study 39509229 — intervention group
Group type: EXPERIMENTAL
Intervention: Women reporting PMIEs on the MIES
Number of subjects: 0
Study 39509229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in PMIE reporting
Number of subjects: 0
Study 39509231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 200
Study 39509231 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (pharmacotherapy)
Number of subjects: 200
Study 39509248 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 4
Study 39509248 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet automated endothelial keratoplasty (DAEK)
Number of subjects: 4
Study 39509246 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-MY6349 PET/CT
Number of subjects: 90
Study 39509387 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index (elevated)
Number of subjects: 1538
Study 39509387 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index (highest group > 10)
Number of subjects: 1538
Study 39509387 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index (highest group)
Number of subjects: 1538
Study 39509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis screening during the first trimester (54%), second trimester (29%), and third trimester (13%).
Number of subjects: 147
Study 39509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis diagnosed in the second or third trimester.
Number of subjects: 147
Study 39509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women without healthcare insurance (25%).
Number of subjects: 147
Study 39509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns exposed to T. pallidum in utero.
Number of subjects: 147
Study 39509672 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 583
Study 39509672 — intervention group
Group type: COMPARATOR
Intervention: No axillary lymph node dissection (ALND)
Number of subjects: 583
Study 39509672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 583
Study 39509704 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-Reducing Salpingectomy and Oophorectomy
Number of subjects: 0
Study 39509704 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39509708 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-ADL-PDT (160mg/g MAL cream)
Number of subjects: 224
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD4TB v7
Number of subjects: 1392
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HR
Number of subjects: 1392
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 1392
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB [sequential negative]
Number of subjects: 1392
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-CAD4TB [sequential negative]
Number of subjects: 1392
Study 39509711 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB [sequential positive]
Number of subjects: 1392
Study 39509838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) every four weeks (Q4W)
Number of subjects: 121
Study 39509838 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) every two weeks (Q2W)
Number of subjects: 121
Study 39509838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 39509838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q4W (achieved CII)
Number of subjects: 121
Study 39510242 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal Splint (OS)
Number of subjects: 60
Study 39510242 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A (BTX-A)
Number of subjects: 60
Study 39510242 — intervention group
Group type: COMPARATOR
Intervention: Both OS and BTX-A
Number of subjects: 60
Study 39510247 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure for 25 minutes daily for 5 or more days
Number of subjects: 43
Study 39510247 — intervention group
Group type: COMPARATOR
Intervention: Red light exposure for 25 minutes daily for 5 or more days (placebo)
Number of subjects: 43
Study 39510247 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure
Number of subjects: 43
Study 39510322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5xICS (inhaled corticosteroids)
Number of subjects: 0
Study 39510322 — intervention group
Group type: COMPARATOR
Intervention: 1xICS (inhaled corticosteroids)
Number of subjects: 0
Study 39510519 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mm mini-implants
Number of subjects: 24
Study 39510519 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mm mini-implants
Number of subjects: 24
Study 39510586 — intervention group
Group type: EXPERIMENTAL
Intervention: CD70-Targeted Immuno-PET/CT Imaging
Number of subjects: 0
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-containing supplements (mainly multivitamins) taken prepregnancy/early pregnancy
Number of subjects: 629
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin < 60 μg/L
Number of subjects: 629
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin < 15 μg/L
Number of subjects: 629
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin < 30 μg/L
Number of subjects: 629
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: sTfR > 4.4 mg/L
Number of subjects: 629
Study 39510727 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI < 0 mg/kg
Number of subjects: 629
Study 39510769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic genotype-guided statin prescription
Number of subjects: 225
Study 39510769 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care statin prescription
Number of subjects: 225
Study 39510773 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based leadership training group
Number of subjects: 119
Study 39510773 — intervention group
Group type: COMPARATOR
Intervention: Conventional online training group
Number of subjects: 119
Study 39510773 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 119
Study 39510778 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination hesitancy across survey waves
Number of subjects: 13571
Study 39510778 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with vaccination willingness
Number of subjects: 13571
Study 39510778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived financial status
Number of subjects: 13571
Study 39510778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender influence on vaccination willingness
Number of subjects: 13571
Study 39510783 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable gadget to remind users to break sitting time, coupled with a brief health coaching session, pamphlet, and reminder messages
Number of subjects: 0
Study 39510783 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 39510786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 0
Study 39510786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39510785 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with ropivacaine
Number of subjects: 100
Study 39510785 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic wound infiltration
Number of subjects: 100
Study 39510784 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, multimodal prehabilitation programme (exercise, nutrition and psychosocial support) supported through an online platform for 3-12 weeks.
Number of subjects: 144
Study 39510784 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative care
Number of subjects: 144
Study 39510803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum (QL) block
Number of subjects: 153
Study 39510803 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominus plane (TAP) block
Number of subjects: 153
Study 39510803 — intervention group
Group type: COMPARATOR
Intervention: Opioid consumption at 24 hours
Number of subjects: 153
Study 39510803 — intervention group
Group type: COMPARATOR
Intervention: Pain scores
Number of subjects: 153
Study 39510803 — intervention group
Group type: COMPARATOR
Intervention: Opioid-related side effects
Number of subjects: 153
Study 39510809 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-PGA
Number of subjects: 22
Study 39510809 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-CAI
Number of subjects: 22
Study 39510809 — intervention group
Group type: COMPARATOR
Intervention: BB
Number of subjects: 22
Study 39511001 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser hemorrhoidoplasty
Number of subjects: 48
Study 39511001 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 48
Study 39511164 — intervention group
Group type: EXPERIMENTAL
Intervention: benmelstobart (1200 mg) plus anlotinib (10 mg) plus paclitaxel (135 mg) for 4-6 cycles (21-day)
Number of subjects: 0
Study 39511164 — intervention group
Group type: EXPERIMENTAL
Intervention: benmelstobart (1200 mg) plus anlotinib (10 mg) plus chemotherapy
Number of subjects: 0
Study 39511203 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA (2.7 g/day)
Number of subjects: 33
Study 39511203 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA (dose-dependent)
Number of subjects: 33
Study 39511367 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for one-year stroke prediction
Number of subjects: 26183
Study 39511367 — intervention group
Group type: COMPARATOR
Intervention: Current clinical risk scores
Number of subjects: 26183
Study 39511473 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium group (individuals exhibiting delirium at least once)
Number of subjects: 0
Study 39511473 — intervention group
Group type: COMPARATOR
Intervention: Non-delirium group (remainder of individuals)
Number of subjects: 0
Study 39511473 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 0
Study 39511476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2-0.7 mcg/kg/h)
Number of subjects: 0
Study 39511476 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 0
Study 39511504 — intervention group
Group type: EXPERIMENTAL
Intervention: Giomer sealant with etching (intervention group)
Number of subjects: 52
Study 39511504 — intervention group
Group type: COMPARATOR
Intervention: Giomer sealant without etching (control group)
Number of subjects: 52
Study 39511506 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron group
Number of subjects: 216
Study 39511506 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 216
Study 39511571 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit strategy (education, redesign workbooks, online learning community, remote coaching)
Number of subjects: 20
Study 39511611 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/d) with standard of care concurrent chemoradiotherapy (cCRT)
Number of subjects: 0
Study 39511611 — intervention group
Group type: COMPARATOR
Intervention: Standard of care concurrent chemoradiotherapy (cCRT) without metformin
Number of subjects: 0
Study 39511631 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced microeconomic intervention including 12 weekly educational group sessions, employment-focused mentoring, and an unconditional grant of US $1200.
Number of subjects: 0
Study 39511631 — intervention group
Group type: COMPARATOR
Intervention: Usual care including US $250 in emergency assistance and peer support for legal gender affirmation.
Number of subjects: 0
Study 39511648 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with decision support
Number of subjects: 51
Study 39511648 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring without decision support
Number of subjects: 51
Study 39511648 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 39511666 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, family-supported, patient-centred ACP programme (ACP-Family)
Number of subjects: 170
Study 39511666 — intervention group
Group type: COMPARATOR
Intervention: Usual ACP care (ACP-UC)
Number of subjects: 170
Study 39511701 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39511777 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-every-6-months (PP6M)
Number of subjects: 702
Study 39511777 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate once-every-3-months (PP3M)
Number of subjects: 702
Study 39511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV)
Number of subjects: 375
Study 39511789 — intervention group
Group type: COMPARATOR
Intervention: Bipolar voltage (BV)
Number of subjects: 375
Study 39511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV) in CPVI alone cohort
Number of subjects: 375
Study 39511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV) in CPVI plus cohort
Number of subjects: 375
Study 39511836 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 25
Study 39511836 — intervention group
Group type: COMPARATOR
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 25
Study 39511836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SEMA and TRT)
Number of subjects: 25
Study 39512280 — intervention group
Group type: EXPERIMENTAL
Intervention: ublituximab
Number of subjects: 0
Study 39512280 — intervention group
Group type: COMPARATOR
Intervention: teriflunomide
Number of subjects: 0
Study 39512729 — intervention group
Group type: EXPERIMENTAL
Intervention: biweekly counseling (120 min over 8 weeks)
Number of subjects: 99
Study 39512729 — intervention group
Group type: EXPERIMENTAL
Intervention: one-time check-in (30 min) with a dietitian
Number of subjects: 99
Study 39512761 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 48781
Study 39512761 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent standard-dose, inactivated influenza vaccine (SD-IIV4)
Number of subjects: 48781
Study 39512897 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention (AAI)
Number of subjects: 39
Study 39512897 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 39
Study 39513018 — intervention group
Group type: EXPERIMENTAL
Intervention: RVGLS/PASP ratio
Number of subjects: 2865
Study 39513018 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with reduced ejection fraction
Number of subjects: 2865
Study 39513018 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with mildly reduced ejection fraction
Number of subjects: 2865
Study 39513018 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with preserved ejection fraction
Number of subjects: 2865
Study 39513018 — intervention group
Group type: EXPERIMENTAL
Intervention: RVGLS/PASP ratio ≤0.32
Number of subjects: 2865
Study 39513023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab (12 mg/day, total 60 mg)
Number of subjects: 24
Study 39513023 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alemtuzumab (12 mg/day, total 36 mg)
Number of subjects: 24
Study 39513044 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, repeated transcranial alternating current stimulation (tACS) sessions
Number of subjects: 7
Study 39513186 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 400 mg
Number of subjects: 438
Study 39513186 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 100 mg
Number of subjects: 438
Study 39513186 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 25 mg
Number of subjects: 438
Study 39513186 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 438
Study 39513224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Number of subjects: 0
Study 39513255 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised, moderate-intensity exercise training program (3 h/wk)
Number of subjects: 59
Study 39513255 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 59
Study 39513267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous BNP (0.005 µg/kg per minute)
Number of subjects: 67